The crosstalk between hormone- and EGFR-family pathways is considered a possible cause of hormone-resistance. To evaluate the effects of a combined blockade of these two pathways, we activated an international multicentre phase IIb double blind randomized trial in neoadjuvant setting.
LET-LOB: preoperative letrozole plus lapatinib or placebo in hormone-receptor positive HER2 negative operable breats cancer. Preliminary report of activity and cardiac tolerability / Frassoldati, A., Guarneri, V., Cagossi, K., Bottini, A., Cavanna, L., Jovic, G., Piacentini, F., Oliva, C., Conte, P.. - In: BREAST CANCER RESEARCH AND TREATMENT. - ISSN 0167-6806. - STAMPA. - 10s, S1 (abstract 2087):(2007), pp. s114-s114. (30th Annual San Antonio Breast Cancer Symposium San Antonio, TX December 13-16, 2007).
LET-LOB: preoperative letrozole plus lapatinib or placebo in hormone-receptor positive HER2 negative operable breats cancer. Preliminary report of activity and cardiac tolerability
GUARNERI, Valentina;JOVIC, Gordana;PIACENTINI, Federico;CONTE, Pierfranco
2007
Abstract
The crosstalk between hormone- and EGFR-family pathways is considered a possible cause of hormone-resistance. To evaluate the effects of a combined blockade of these two pathways, we activated an international multicentre phase IIb double blind randomized trial in neoadjuvant setting.
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
